The CYP2C8 enzyme is involved in paclitaxel metabolism, but only one woman with a breast cancer-related event had been treated with a paclitaxel-based regimen and four other women with events had received a docetaxel-based regimen as neoadjuvant treatment. This evidence concerns the gene CYP2C8 and breast carcinoma.